Several population pharmacokinetic (popPK) models for ciclosporin (CsA) in adult renal transplant recipients have been constructed to optimize the therapeutic regimen of CsA. However, little is known about their predictabilities when extrapolated to different clinical centres. Therefore, this study aimed to externally evaluate the predictive ability of CsA popPK models and determine the potential influencing factors.
Introduction
Ciclosporin (CsA), a cyclic polypeptide with potent immunosuppressant properties, is widely used to prevent graft-vs.-host disease after renal transplantation [1] . As the first clinically used calcineurin inhibitor, CsA greatly improves the survival rate of transplant patients, especially the short-term outcome, and has been the most important component of combined immunosuppressive regimens [2] .
CsA pharmacokinetics (PK) have been extensively evaluated. Because of its erratic gastrointestinal absorption and the combined activity of cytochrome P450 (CYP) 3A and P-glycoprotein (P-gp) [1] , the oral bioavailability of CsA is approximately 25%; however, it varies from 10 to 89% [3] . To reduce the variability in oral absorption, a microemulsion of CsA (Neoral ® , Novartis) has been formulated [4] . CsA is extensively distributed in peripheral tissues and binds to erythrocytes and plasma proteins [5] [6] [7] . Further, CsA is primarily metabolized by CYP3A4 and CYP3A5 [8] and then eliminated in the bile [9, 10] . Because of its narrow therapeutic range and the marked variability in its PK [11] , close therapeutic drug monitoring (TDM) has been suggested to support CsA dosage adaption. The use of population pharmacokinetic (popPK) models combined with Bayesian estimations to guide CsA dose adaption is more precise than depending only on the personal experiences of transplant physicians [12] . Currently, various popPK models have been developed to quantitatively describe the PK characteristics of CsA [13] . Compared to conventional PK approaches, popPK is a powerful tool used to analyse sparse TDM data from highly diversified patient populations, estimate intra-and interindividual variabilities, and identify the impact of available covariates to evaluate the sources of variability in drug exposure.
Although various popPK models have been built to quantify sources of variability, little is known about their clinical application since full evaluation procedures are lacking [13, 14] . Only one-third of popPK studies on CsA have evaluated the models [13] . Moreover, when models are extrapolated to other clinical centres, more rigorous evaluations need to be undertaken to assess model transferability [15, 16] . Assessing model transferability may help identify potential centre-based factors that influence model predictability and determine whether published popPK models are appropriate for use at any one centre. In addition, adopting the most appropriate popPK model for optimizing dosage regimens using a relatively small number of subjects is more cost-effective than performing a complete popPK study.
In the present study, we hypothesized that all published models represent the PK characteristics of study cohorts. The predictabilities of published popPK models for CsA in adult renal transplants patients were systematically evaluated using an independent data set collected at Huashan Hospital (Shanghai, China). Additionally, potential factors influencing model predictability were investigated.
Materials and methods

Review of published popPK studies on CsA
A systematic literature search for data published on popPK models for CsA until 31 December 2016 was conducted from the following electronic databases: PubMed, Web of Science, Embase, China National Knowledge Infrastructure (www. cnki.net), China Biological Medicine (www.sinomed.ac.cn), and Wanfang (www.wanfangdata.com.cn). The language was limited to English and Chinese. The reference lists of identified reports were also screened. Articles were included in this study if they contained data analysing PK parameters for CsA in adult kidney transplant recipients using the popPK approach. Furthermore, studies were excluded if they were not original, if they focused on patients receiving an emulsion formulation of CsA, if the model parameters were not available for external evaluation, if the data sets overlapped or if the articles were duplicated.
External evaluation data
Patients. Sixty-two adults (44 men and 18 women) who underwent their first renal transplantation at Huashan Hospital from July 2003 to May 2011 were eligible for this study. Demographic and pathophysiological data were retrospectively collected for further evaluation. Patient follow-up was conducted up to 90 days after the surgery, and those with more than five predose concentration (C 0 ) and five 2-h postdose concentration (C 2 ) records were included in the study. A total of 971 CsA whole-blood measurements were collected, including 471 C 0 measurements and 500 C 2 measurements. Patients undergoing dialysis treatment were excluded from this study. The study protocols were approved by the Ethics Committee of Huashan Hospital and written informed consent was obtained from all the subjects. , which was administered as two doses under fasting conditions immediately after surgery. The CsA C 0 and C 2 were regularly monitored to adjust the dosage and achieve the target concentrations, which were based on guidelines for Chinese patients [17] . Target C 0 values were 200-350 ng ml À1 in the 1 st month, 150-300 ng ml À1 during months 1-3, 100-250 ng ml À1 during months 3-12 and 50-100 ng ml À1 thereafter; target C 2 values were 1000-1500 ng ml À1 in the 1 st month, 800-1200 ng ml À1 during months 1-3, 600-1000 ng ml À1 during months 3-12 and 400-600 ng ml À1 thereafter.
MMF was administered based on body weight (WT) and postoperative days (POD). As such, patients weighing <50 kg were administered 1 g day À1 for the first postoperative month and then 0.75 g day À1 thereafter, patients weighing 50-70 kg were administered 1.5 g day À1 for the first postoperative month and then 1 g day À1 thereafter, and patients weighing >70 kg were administered 2 g day À1 for the first postoperative month and then 1.5 g day À1 thereafter.
Intravenous methylprednisolone was administered at 1 g day À1 during the operation, followed by 0. , and the calibration range was 40-800 ng ml
À1
. When the CsA concentration was >800 ng ml À1 , manual dilution was performed prior to testing [18] . The bioassay methods used in the published studies were diverse. Some methods used reagents that are known to crossreact with CsA metabolites, and systematic biases existed [19] ; therefore, the following formulas obtained from large clinical studies were used to convert C 0 values using the corresponding analytical methods before further analyses were performed.
(1) [18] HPLC ¼ 0:96ÂAxSYM À 17:41 (2) [18] RIA ¼ 1:06ÂAxSYM À 5 (3) [20] EMIT ¼ 0:86ÂAxSYM þ 1:98 (4) [19] CEDIA ¼ 0:88ÂAxSYM þ 4:47 (5) [19] where TDx and AxSYM represent the FPIA performed using TDx ® (or TDxFLx ® ) and AxSYM ® analysers, respectively;
HPLC represents high-performance liquid chromatography;
and RIA, EMIT and CEDIA represent radioimmunoassay, enzyme multiplied immunoassay technique and cloned enzyme donor immunoassay, respectively. At 2 h post dosing, most of the CsA administered to a patient exists as the parent drug. In addition, few CsA metabolites cross-react with the antibodies used in immunoassays [1, 21] ; therefore, C 2 values were not converted for the different bioassays.
Genotyping. Four single nucleotide polymorphisms: CYP3A5*3, MDR1 C1236T, G2677 T/A, and C3435T were genotyped by an independent external contractor (GeneCore Biotechnology Co., Ltd., Shanghai, China) via a DNA sequencing apparatus (Applied Biosystems 3730; Thermo Fisher Scientific, Waltham, MA, USA). The results were then compared with standard allele frequencies using the Hardy-Weinberg equilibrium. More details are provided in Text S1.
External evaluation
An external evaluation was conducted using the NONMEM ® software package (version 7.3; ICON Development Solutions, Ellicott City, MD, USA) in conjunction with Intel Fortran XE 2011 Update 13 (Intel Corp, Santa Clara, CA, USA). Post processing of the NONMEM output was programmed using R software (version 3.3.0, http://www.r-project.org/). PopPK models were rebuilt and parameters were fixed as reported by each study. Prediction-and simulation-based diagnostics and Bayesian forecasting were then used to evaluate the predictive performance of the candidate models.
Prediction-based diagnostics. Population predicted concentrations (PRED) were estimated, and the prediction error [PE%, equation (6) ] for each patient was calculated by comparing the PRED to the corresponding observations (OBS).
The accuracy and precision of each candidate model were investigated using median prediction error (MDPE) and median absolute prediction error (MAPE), respectively [22] . The percentage of |PE|% within 20% (F 20 ) and 30% (F 30 ) was also calculated. The metrics of a candidate model were arbitrarily considered to be clinically acceptable when the standards of MDPE ≤ ± 15%, MAPE ≤30%, F 20 > 35% and F 30 > 50% were reached, as previously reported [23] .
Simulation-based diagnostics. By comparing the appropriate statistics from the simulated and evaluation data, the predictability of each candidate model was assessed via simulation-based diagnostics [24, 25] . The normalized prediction distribution error (NPDE) was determined using an add-on R package (NPDE, version 2.0, www.npde.biostat. fr) [26] . Overall, 2000 data sets were simulated according to the reported final model parameters. Based on the null hypothesis that a candidate model is robust enough to describe the evaluation data, diagnostic graphs and statistic tests were conducted to examine whether the NPDE data followed a standard normal distribution. The Wilcoxon signed-rank test was used to determine whether the mean NPDE was significantly different from 0, and Fisher's test was used to determine whether the variance was significantly different from 1. Additionally, the ShapiroWilks test was used to determine whether the observed distribution was significantly different from a normal distribution [26] . The global test, which considers the above three tests using the Bonferroni correction, was also used in the analysis [27] .
Bayesian forecasting. To assess the influence of prior observed concentrations on model predictability, maximum a posteriori Bayesian (MAPB) forecasting was conducted using NONMEM. The relative difference of the last observation, denoted by the individual PE% [IPE%, equation (7)], was calculated for this analysis. The all data method, in which forecasting is based on all available prior observations, was adopted for the estimation [28] . The individual prediction (IPRED) of the last observation was estimated based on the last one, two, three and four prior observations. More details are included in Text S2.
Median IPE%, median absolute IPE%, and F 20 and F 30 of IPE% (IF 20 and IF 30 , respectively) were used to evaluate the predictability as prior information increased.
The impact of structural models Different modelling strategies were used in the selected studies that may have affected the predictive performance of the models. Therefore, to explore the impact of modelling strategy, the predictability of different structural models with or without the most involved covariates was evaluated. The evaluation approaches consisted of prediction-and simulation-based diagnostics and Bayesian forecasting, as described above.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [29] , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2015/16 [30] .
Results
Review of published popPK studies on CsA
After the literature search ( Figure 1 and Text S3), 17 popPK studies on CsA [12, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] were identified for external evaluation. Ten of the studies were conducted in East Asian countries (six in China [33, 36, 38, 41, 43, 44] , two each in Japan [32, 34] and Korea [45, 46] ), seven in Europe (three in France [35, 37, 40] , one each in Norway [12] and the Netherlands [42] and two in Spain [31, 39] ). Additionally, Studies identified for external evaluation (n=17) Figure 1 Overview of the strategy used in the literature search. n: number of articles returned by search Table 1 Summary of published population pharmacokinetic studies of ciclosporin in adult renal transplant recipients External evaluation of popPK models for CsA Table 1 (Continued) of the studies were conducted using a small sample size of fewer than 100 subjects [12, 31, 32, 35-37, 39, 40, 42, 43, 45, 46] . Six bioassay methods were used in 17 studies, FPIA was used in 12 studies, and HPLC, EMIT, CEDIA and RIA were used in the remaining five studies (Table 1) . For the 14 compartmental models, the absorption phase was described most frequently by first-order kinetics [12, 32, 34, 36, 38, 39, [43] [44] [45] [46] . Zero-order kinetics [37] , transit [42] and Erlang [35, 40] models were also used in some of the studies. CsA disposition was described using one-compartmental models in six studies with sparse sampling designs [36, 38, 39, [43] [44] [45] . Two-compartmental models were used in all eight of the studies that included intense sampling [12, 32, 34, 35, 37, 40, 42, 46] . All compartmental models were characterized using linear kinetics and first-order elimination.
In addition to the linear compartmental model, a nonlinear Michaelis-Menten (MM) empirical formula [equation (8) ] was used to quantify the relationship between daily dose and C 0 in three studies [31, 33, 41] as follows:
where V m denotes the maximum dose rate (daily dose), K m denotes the steady-state C 0 at half-maximal dose rate and C represents the C 0 of CsA. Most of the studies were carried out using triple immunosuppressive therapy; however, the studies by Yoshida et al. [32] , Rousseau et al. [35] and Lukas et al. [39] did not provide this information. The dose ranges of CsA for linear compartmental and nonlinear MM models were 50-1200 mg day À1 and 50-700 mg day À1 , respectively. The details are summarized in Table S1 . Overall, 15 different covariates were incorporated into the final models used in the studies. WT, POD and age were the three most frequently identified covariates in the final models and were reported in 12, six and five studies, respectively ( Figure S1 ). Moreover, CYP3A5*3 and MDR1 polymorphisms were screened in five and three studies, respectively; however, they were both reported in one study.
External evaluation
Patients. The demographic and pathophysiological data, as well as concomitant medications collected for the evaluation are summarized in Table 2 according to the incorporated covariates. No patient was coadministered a calcium channel blocker, verapamil or diltiazem in our data set. All the allele frequencies of CYP3A5*3 and MDR1 genetic polymorphisms were in Hardy-Weinberg equilibrium (Table 3 ). There were three observations (C 0 ) below the limit of detection; however, they are included in the analysis as the original reported values.
Prediction-based diagnostics. C 0 was used to evaluate the predictability of models that were developed using linear compartmental or nonlinear MM structural models. In contrast, C 2 was used to evaluate predictability based on compartmental structural models. For C 0 , prediction-based diagnostics showed that the nonlinear MM models by Rui Figure 2 and Table S2 .
Simulation-based diagnostics. Regarding the simulationbased NPDE diagnostics, the mean value and Wilcoxon signed-rank test for C 0 performed relatively well, while the distribution of NPDE was uniform, indicating an inconsistency between the evaluation and simulated data, especially for variance. Only the global test P-value based on the linear compartmental model developed by Press et al. [42] was >0.01, indicating the simulation was appropriately applied. None of the NPDE distributions of nonlinear MM models satisfied the expected distribution N (0, 1). Similar to the results observed for C 0 , the linear compartmental models did not perform well for C 2 (Table S3 ). In contrast to the prediction-based diagnostic results, the nonlinear MM models underperformed in the C 0 analysis and may not be appropriate for simulation-based applications. As shown in Figure 3 , the NPDE of the MM model by Wang et al. [41] , which had the best predictive performance in the PE% test, did not follow a normal distribution. The NPDE graphics and statistical tests for all the models are presented in Figure  S2 and Table S3 .
Bayesian forecasting. Bayesian forecasting demonstrated that prior knowledge substantially improves the prediction accuracy of all models, including poor prediction models [32, 34, 38, 46] , indicating that a popPK model combined with Bayesian estimation is useful for CsA dosage adjustments. After two or three prior observations were available, model predictability reached a stable state and additional prior observations did not necessarily imply further improvement. Moreover, nonlinear MM models performed better than linear compartmental models did, and most models had IF 20 values of ≥80% vs. 35% after information from one prior observation was available. The metric results and box plots are presented in Figure 4 and Table S4 , respectively.
The impact of structural models
The nonlinear MM model performed significantly better than the prediction-based evaluations of one-compartmental and two-compartmental models ( Figure 5 and Table S2 ). The IF 20 of the nonlinear MM base model showed a remarkable improvement over that of the other two linear compartmental base models for C 0 (69.21% vs. 34.39% and 33.12%) and C 2 (63.00% vs. 36.60% and 36.40%). After incorporating the three most identified covariates (WT, POD and age) into the model, the IF 20 of the nonlinear MM model and the other two linear compartmental models for C 0 were 82.59%, 33.76% and 32.48%, respectively, and for C 2 were 79.20%, 39.40% and 39.20%, respectively. Improvements were more significant in nonlinear MM models than those in linear compartmental models. Moreover, the predictive performance of linear compartmental models was much worse than that of MM base models, even after the inclusion of covariates (< 40% vs. >63%). These results imply that improvements resulting from nonlinear MM models were considerably more than those resulting from incorporating covariates.
Normality for the prediction discrepancies of the MM model was unsatisfied in the simulation-based diagnostics, which is consistent with the results of the above final models (Table S3 and Figure S3 ). The parameter estimates are listed in Table S5 .
The predictive performance of the structural models improved for both C 0 and C 2 with MAPB. The IF 20 values for the MM base models after Bayesian forecasting reached ≥85%, demonstrating that these models are superior to the linear compartmental base models, which reached ≤45%. Box plots are presented in Figure 6 and results are displayed in Table S4 .
Discussion
Although nearly 20 CsA popPK studies have been conducted in adult renal transplant patients, most of these studies were single centre-based and predictability was not fully evaluated. Therefore, it is necessary to assess the accuracy and robustness of a model before it is extrapolated to another clinical centre [47] .
To the best of our knowledge, this is the first study to evaluate published popPK models of CsA systematically in adult renal transplant patients using an independent data set. Although the data set used in this study was taken from one centre, the conclusions could be helpful when further investigating CsA.
To minimize discrepancies between studies, models developed using adult renal transplant recipients who received Neoral-based triple immunosuppressive therapy were evaluated. Large variabilities in predictive performance exist in the published models, as demonstrated by conducting evaluations using our data set. After comparing the impact of structural models on predictability, we concluded that the predictability of nonlinear MM models is superior to that of linear compartmental models, indicating that the PK of CsA is nonlinear.
CsA is believed to follow linear PK when administered at its normal dose range. This observation is based on a clinical PK study of stable renal transplant patients who were intravenously administered CsA at three dosage levels (1.25, 2.5 and 5 mg kg À1 day À1 ) [48] . However, the influence of absorption on CsA PK was not investigated. The same research group reported nonlinear PK in renal transplant patients who were taking oral CsA in 1993, as determined by popPK analyses [49] . CsA is a highly lipophilic cyclic polypeptide; therefore, its absorption is problematic [50] . The nonlinearity of CsA absorption and disposition was shown by comparing PK The allele frequencies are found to be in Hardy-Weinberg equilibrium (P > 0.05) healthy volunteers [51] . A new oral microemulsion of CsA (Neoral ® ) was formulated to reduce the variability and improve the dose linearity of CsA [4] . Mueller et al. [52] compared the PK of Neoral with those of a conventional CsA formulation and concluded that the linearity of Neoral is better. However, it should be noted that this study was conducted in healthy volunteers who were administered a single oral dose of CsA; therefore, inconsistencies in the pathophysiological features between transplant patients and healthy volunteers may have influenced the PK behaviour of CsA. The nonlinearity of CsA PK in renal transplant patients could be attributed to many factors. During the early postoperative period, recovery of gastrointestinal function may increase CsA bioavailability with POD, resulting in nonlinear kinetics [36, 40, 44, 53] . Further, the inhibitory effects of CsA on CYP3A4 and P-gp can lead to autoinhibition and dose-dependent PK, which may also be partially attributed to the nonlinearity [54] [55] [56] . In addition, an important steroid X receptor regulates CYP3A and MDR1 gene expression; therefore, tapering steroid doses during immunosuppressive therapy may reduce the expression of CYP3A and MDR1.
However, this could result in increased absorption and accelerated metabolism of CsA [57, 58] .
The studies conducted by Reymond et al. [51] and Mueller et al. [52] show that the terminal half-life of CsA increases as the dosage is increased, indicating a nonlinear disposition. Saturation of hepatic metabolism would partly be responsible for this phenomenon [51] . Moreover, since CsA is a highextraction drug, recovery of hepatic function after transplantation may decrease its bioavailability [46] . TDM has shown that individuals with higher drug clearance rates may have lower drug concentrations, resulting in a tendency for clinicians to prescribe higher doses. When a correlation between the clearance and daily dose of CsA is observed, it may be misinterpreted as nonlinearity [59] . However, when patients are sampled at more than three or four dose levels, the effects of TDM described above may not influence the judgement of nonlinearity [59] .
Compared to linear compartmental models, nonlinear MM models are data-driven empirical models that are not based on hypotheses of one or two compartments. Therefore, such models can only be used to describe CsA daily dose and steady-state concentration relationships and Box plots of individual prediction error with Bayesian forecasting for 17 published population pharmacokinetic models in different scenarios (0 represents predictions without prior information and 1-4 represent predictions with one to four prior observations, respectively). In scenario n, prior n observations were used to estimate the individual prediction and it was then compared with the corresponding observation. (A) Predose concentration (C 0 ) and (B) 2-h postdose concentration (C 2 ) are shown cannot be used to describe the full concentration-time course of CsA. Development of all three MM models was based on C 0 , and they can therefore be used to predict C 0 ; however, these MM models cannot be used to appropriately extrapolate C 2 .
In addition to the structural model discussed above, study design, ethnic differences and retained covariates were all potential centre-based factors that may have resulted in interstudy variability and influenced model predictability [60] . Minor differences in predictive performance were observed between sparse and intensive sampling design studies, which may be attributable to insufficient information from the sparse samples to precisely estimate apparent clearance (CL/F) [61] .
In the present study, models that performed best for C 0 and C 2 were all developed in Chinese patients, indicating that ethnicity potentially influences model transferability. It is believed that similarities in the ethnic background of patients may result in similar genetics, prescribing, and dietary habits. However, this was not observed for tacrolimus (TAC), another commonly used calcineurin inhibitor [23] , which is also a substrate of CYP3A4/5 and the P-gp transporter. The failure of ethnicity to influence the PK of TAC may be attributed to the CYP3A5*3 polymorphism, which was identified as an important covariate for the CL/F of TAC [62] . However, no widely acceptable genetic polymorphisms have been identified as an influential factor in the PK of CsA.
The linear compartmental model developed by Liang et al. [38] using a Chinese population did not perform well with a typical estimated CL/F of 15.3 l h À1 , which was less than the 17.0-50.4 l h À1 reported for 13 other published compartmental models; however, the characteristics of the study cohort were comparable to those of the other studies conducted in Chinese patients. The reason for this is unknown; however, it is noteworthy that, Liang et al. [38] used the SAS program to perform popPK analyses, whereas NONMEM was used in the other studies.
As most covariates were screened based on pharmacostatistical considerations, there was no consensus on whether the involved covariates had been achieved in published models. WT, POD and age were the three most frequently identified covariates influencing the CL/F of CsA. It is noteworthy that the covariates identified in published studies were dependent on the study population and may not necessarily reflect the external evaluation population. Although some linear compartmental models performed unsatisfactorily in the prediction-based diagnostics, Bayesian forecasting indicated that popPK modelling combined with MAPB estimation is a useful tool to guide clinical TDM [63] . With the original population parameter estimates being prior distributions, personalised dosage regimens could be designed using Bayesian forecasting and the available concentrations [64, 65] . Predictability became stable when 2-3 prior observations were available, which is consistent with the results obtained for TAC [23] . Additional prior observations did not necessarily imply further improvement. Undeniably, there are some limitations to our study. Bioassay type is an important factor that may influence model transferability [19, 60] . In the present study, the bioassay methods used in the published studies were diverse. To reduce systematic bioassay biases, various equations based on the assay methods were used [18] [19] [20] . After conversion, no obvious bioassay-related trends were found in the predictive performance analyses. In addition, most F 20 values for published models changed <5% when the sensitivity analysis was conducted by changing the slope of conversion formulas by ±10%. Moreover, as external evaluation data were retrospectively collected during routine TDM, patient compliance could not be ascertained. Although sparse samples could be used to estimate CL/F precisely [61] , no intensive samples were available to evaluate the biological plausibility of absorption models such as the transit and Erlang models.
In conclusion, published CsA popPK models in adult renal transplant recipients were externally evaluated using an independent data set. The prediction-based diagnostics show that ethnicity is a potential factor that may influence model transferability. The simulation-based diagnostics showed variance inconsistencies in most of the published models. By investigating the impact of structural models, we demonstrated that the predictability of nonlinear MM models is superior to that of linear compartmental models, indicating the underlying nonlinear kinetics of CsA. Moreover, popPK modelling combined with MAPB estimation was found to be a useful tool to guide CsA dose adjustments.
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